

ORAL PRESENTATION

Open Access

Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment-naïve, HIV-1-infected patients

C Cohen^{1*}, JM Molina², P Cahn³, B Clotet⁴, J Fourie⁵, B Grinsztejn⁶, W Hao⁷, M Johnson⁸, K Supparatpinyo⁹, HM Crauwels¹⁰, L Rimsky¹⁰, S Vanveggel¹⁰, P Williams¹⁰, K Boven¹¹

From Tenth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 7-11 November 2010

Introduction

Pooled 48-week primary analysis results of two double-blind, randomised, TMC278 Phase III trials, ECHO (TMC278-C209, NCT00540449) and THRIVE (TMC278-C215, NCT00543725), are presented.

Methods

Treatment-naïve adult patients (N=1368) received (1:1) TMC278 25mg qd or EFV 600mg qd, plus TDF/FTC (ECHO), or TDF/FTC, AZT/3TC or ABC/3TC (THRIVE). The primary objective was to demonstrate non-inferiority (12% margin) of TMC278 to EFV in confirmed virologic response (viral load [VL] <50 copies/mL ITT-TLOVR algorithm) at Week 48.

Results

Overall virologic response rates at Week 48 were high (Figure 1). TMC278 showed non-inferior efficacy versus EFV. The impact of adherence, in addition to other factors, such as baseline viral load and exposure, on virologic response will be presented. Incidences of the following tolerability measures were significantly lower in the TMC278 group than in the EFV group: adverse events (AEs) leading to discontinuation (3% vs. 8%, respectively; $p=0.0005$), grade 2-4 AEs at least possibly related to treatment (16% vs. 31%; $p<0.0001$), rash (3% vs 14%; $p<0.0001$), dizziness (8% vs. 26%; $p<0.0001$),

abnormal dreams/nightmare (8% vs. 13%; $p=0.0061$), and grade 3/4 laboratory abnormalities for lipids ($p\leq 0.001$).

Conclusions

At Week 48, TMC278 demonstrated a high virologic response rate ($\geq 83\%$) and non-inferior efficacy versus EFV when administered with NRTIs in both Phase III trials. The virologic failure rate was significantly higher with TMC278, while the incidences of AEs leading to discontinuation were significantly lower with TMC278. Grade 2-4 AEs at least possibly related to treatment were half as frequent with TMC278 compared with EFV. In addition, incidences of dizziness, abnormal dreams/nightmare and rash were significantly lower for TMC278, and TMC278 had significantly fewer grade 3/4 lipid abnormalities than EFV.

Author details

¹Community Research Initiative of New England, Boston, MA, USA. ²Saint-Louis Hospital and University of Paris, Department of Infectious Diseases, Paris, France. ³Hospital Juan A Fernández and Fundación Huesped, Buenos Aires, Argentina. ⁴Hospital Universitari Germans Trias i Pujol and IrsiCaixa Foundation, UAB, Barcelona, Spain. ⁵Dr J Fourie Medical Centre, Dundee, KwaZulu Natal, South Africa. ⁶Instituto de Pesquisa Clínica Evandro Chagas-Fiocruz, Rio de Janeiro, Brazil. ⁷Beijing You'an Hospital, Beijing, China. ⁸Royal Free Hospital, London, UK. ⁹Chiang Mai University, Section of Infectious Disease, Chiang Mai, Thailand. ¹⁰Tibotec BVBA, Beersse, Belgium. ¹¹Tibotec Inc, Titusville, NJ, USA.

¹Community Research Initiative of New England, Boston, MA, USA
Full list of author information is available at the end of the article

	TMC278 25mg qd (n=686)	Efavirenz 600mg qd (n=682)	Difference between groups
Efficacy (Week 48 outcomes)			
VL <50 copies/mL (ITT-TLOVR), % [95% CI]*	84	82	2.0 [-2.0,6.0]
ECHO, n (%) [95% CI]	287/346 (83)	285/344 (83)	0.1 [-5.5,5.7]
THRIVE, n (%) [95% CI]	291/340 (86)	276/338 (82)	3.9 [-1.7;9.5]
VL <50 copies/mL (per-protocol, ITT-TLOVR), n (%) [95% CI]	569/669 (85)	548/662 (83)	2.3 [-1.7,6.2]
Virologic failures, [†] %	9	5	ND
Discontinued due to AE/death, %	2	7	ND
Discontinued for other reasons, %	5	6	ND
Mean [95% CI] increase from baseline in CD4 count (NC=F [‡]), cells/mm ³	192 [181,203]	176 [165,188]	NS
Resistance**			
Virologic failure, [§] n	72	39	p=0.0014
Failures with resistance data, n	62	28	ND
Failures developing phenotypic resistance to their treatment NNRTI, n	31/62	12/28	ND
Failures developing NNRTI mutations, n	39/62	15/28	ND
Failures developing IAS-USA NRTI mutations, n	42/62	9/28	ND
Most frequent NNRTI and NRTI mutations	E138K, M184I	K103N, M184V	NA
Safety** , [¶]			
Grade 2–4 AE at least possibly related to treatment, %	16	31	p<0.0001 [#]
Serious AEs, %	7	8	NS
AEs leading to discontinuation, %	3	8	p=0.0005
AEs of interest at least possibly related to treatment[‡], %			
Psychiatric	15	23	p=0.0002 [#]
Abnormal dreams/nightmare	8	13	p=0.0061 [#]
Neurological events of interest	17	38	p<0.0001 [#]
Dizziness	8	26	p<0.0001 [#]
Rash (any type)	3	14	p<0.0001 [#]

ITT-TLOVR = intent-to-treat-time-to-loss of virologic response; CI = confidence interval; ND = not determined because not predefined; NS = non-significant; NA = not applicable. *Based on normal approximation; **p-value for Fisher's Exact test; [†]Rebound or never suppressed; [‡]NC=F = non completer = failure: missing values after discontinuation imputed with change = 0; Last observation carried forward otherwise; [§]Virologic failure determined in the ITT population with all available data, regardless of time of failure and reason for discontinuation; [¶]Safety analyses performed using all available data, including beyond Week 48; [#]Predefined analysis for these AEs: [‡]Observed in ≥10% of patients in the TMC278 group or EFV group and excluding laboratory abnormalities reported as an AE

Figure 1

Published: 8 November 2010

doi:10.1186/1758-2652-13-S4-O48

Cite this article as: Cohen et al.: Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment-naïve, HIV-1-infected patients. *Journal of the International AIDS Society* 2010 **13**(Suppl 4):O48.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

